Seres Therapeutics (MCRB) Revenue & Revenue Breakdown
Seres Therapeutics Revenue Highlights
Latest Revenue (Q)
$351.00K
Main Segment (Y)
License And Service
Main Geography (Y)
License And Service
Seres Therapeutics Revenue by Period
Seres Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $126.33M | 1672.24% |
| 2022-12-31 | $7.13M | -95.08% |
| 2021-12-31 | $144.93M | 336.33% |
| 2020-12-31 | $33.22M | -3.74% |
| 2019-12-31 | $34.51M | 22.07% |
| 2018-12-31 | $28.27M | -11.94% |
| 2017-12-31 | $32.10M | 47.48% |
| 2016-12-31 | $21.77M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Seres Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Seres Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $351.00K | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $5.96M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $64.00K | -79.35% |
| 2023-09-30 | $310.00K | -99.75% |
| 2023-06-30 | $126.47M | -24328.54% |
| 2023-03-31 | $-522.00K | -153.54% |
| 2022-12-31 | $975.00K | -71.69% |
| 2022-09-30 | $3.44M | 183.22% |
| 2022-06-30 | $1.22M | -18.55% |
| 2022-03-31 | $1.49M | -79.32% |
| 2021-12-31 | $7.22M | -94.30% |
| 2021-09-30 | $126.72M | 2307.85% |
| 2021-06-30 | $5.26M | -7.96% |
| 2021-03-31 | $5.72M | -67.44% |
| 2020-12-31 | $17.56M | 1139.52% |
| 2020-09-30 | $1.42M | -76.56% |
| 2020-06-30 | $6.04M | -26.18% |
| 2020-03-31 | $8.19M | 7.44% |
| 2019-12-31 | $7.62M | 8.41% |
| 2019-09-30 | $7.03M | -43.89% |
| 2019-06-30 | $12.53M | 71.17% |
| 2019-03-31 | $7.32M | -31.12% |
| 2018-12-31 | $10.63M | 17.38% |
| 2018-09-30 | $9.05M | 96.34% |
| 2018-06-30 | $4.61M | 16.14% |
| 2018-03-31 | $3.97M | 29.94% |
| 2017-12-31 | $3.06M | -86.72% |
| 2017-09-30 | $23.02M | 663.60% |
| 2017-06-30 | $3.01M | -0.03% |
| 2017-03-31 | $3.02M | -0.69% |
| 2016-12-31 | $3.04M | -76.67% |
| 2016-09-30 | $13.02M | 333.26% |
| 2016-06-30 | $3.00M | 10.85% |
| 2016-03-31 | $2.71M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | - |
Seres Therapeutics generated $351.00K in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Seres Therapeutics Revenue Breakdown
Seres Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 19 |
|---|---|
| License And Service | $27.19M |
Seres Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 19: License And Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|
| License And Service | $5.28M | $10.20M | $8.68M | $4.27M |
| Grant | - | - | - | $341.00K |
Seres Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 19: License And Service (100.00%).
Seres Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 |
|---|---|
| License And Service | $27.19M |
Seres Therapeutics's latest annual revenue breakdown by geography, as of Dec 19: License And Service (100.00%).
Quarterly Revenue by Country
| Country | Dec 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|
| License And Service | $5.28M | $10.20M | $8.68M | $4.27M |
| Grant | - | - | - | $341.00K |
Seres Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 19: License And Service (100.00%).
Seres Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SPRO | Spero Therapeutics | $47.98M | $11.80M |
| SEER | Seer | $14.17M | $4.12M |
| IRD | Opus Genetics | $10.99M | - |
| VTGN | VistaGen Therapeutics | $1.06M | $244.00K |
| APLT | Applied Therapeutics | $455.00K | $1.00M |
| ACTU | Actuate Therapeutics | - | - |
| MCRB | Seres Therapeutics | - | $351.00K |
| INO | Inovio Pharmaceuticals | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| HURA | TuHURA Biosciences | - | - |